Compare NRIX & LZB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRIX | LZB |
|---|---|---|
| Founded | 2009 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2020 | 1994 |
| Metric | NRIX | LZB |
|---|---|---|
| Price | $16.40 | $35.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $30.50 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 820.0K | 322.5K |
| Earning Date | 04-08-2026 | 06-16-2026 |
| Dividend Yield | N/A | ★ 2.75% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.65 |
| Revenue | $76,987,000.00 | ★ $2,349,433,000.00 |
| Revenue This Year | N/A | $1.89 |
| Revenue Next Year | $48.05 | $2.09 |
| P/E Ratio | ★ N/A | $21.48 |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $8.20 | $29.03 |
| 52 Week High | $22.50 | $44.49 |
| Indicator | NRIX | LZB |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 56.82 |
| Support Level | $16.02 | $35.32 |
| Resistance Level | $16.71 | $39.79 |
| Average True Range (ATR) | 0.76 | 0.90 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 36.24 | 66.62 |
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.